Article
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
The Lancet. Oncology - 1 Dec 2016
Long Georgina V, Grob Jean-Jacques, Nathan Paul, Ribas Antoni, Robert Caroline, Schadendorf Dirk, Lane Stephen R, Mak Carmen, Legenne Philippe, Flaherty Keith T, Davies Michael A
Abstract excerpt
BACKGROUND: Dabrafenib plus trametinib treatment provides significant benefits over BRAF-inhibitor monotherapy in patients with BRAFV600E-mutant or BRAFV600K-mutant advanced melanoma; however, in many patients the disease progresses, leading to death. With many treatment options available, understanding clinical factors that predict long-term response and survival for treatments is important for optimisation of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.